Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD.
Target Price
The average target price of RDNT is 87 and suggests 60% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase